Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accounts Payables: 2023-2025

Historic Accounts Payables for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $6.1 million.

  • Immunome's Accounts Payables rose 74.73% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 74.73%. This contributed to the annual value of $14.2 million for FY2024, which is 328.54% up from last year.
  • As of Q3 2025, Immunome's Accounts Payables stood at $6.1 million, which was up 31.91% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Accounts Payables ranged from a high of $14.2 million in Q4 2024 and a low of $2.8 million during Q3 2023.
  • Moreover, its 3-year median value for Accounts Payables was $4.7 million (2025), whereas its average is $5.9 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 328.54% in 2024, then slumped by 33.87% in 2025.
  • Immunome's Accounts Payables (Quarterly) stood at $3.3 million in 2023, then spiked by 328.54% to $14.2 million in 2024, then spiked by 74.73% to $6.1 million in 2025.
  • Its Accounts Payables stands at $6.1 million for Q3 2025, versus $4.7 million for Q2 2025 and $9.1 million for Q1 2025.